Clare I.B. Keddy

Education:  
Lewis and Clark College
Biochemistry and Molecular Biology major
B.A., 2019

Clare is currently in the first year of Medical School training and is rotating through labs while preparing to select a thesis advisor.

Publications:

For work prior to the UMN MSTP

Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA. TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers. bioRxiv [Preprint]. 2024 Jan 19:2024.01.16.575901. PMCID: PMC10827145

Iyer SR, Nusser K, Jones K, Shinde P, Keddy C, Beach CZ, Aguero E, Force J, Shinde U, Davare MA.Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. EMBO Mol Med. 2023 Oct 11;15(10):e17367. PMCID: PMC10565643

Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer Discov. 2023 Mar 1;13(3):598-615. PMCID: PMC9975673

Keddy C, Shinde P, Jones K, Kaech S, Somwar R, Shinde U, Davare MA. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors. Mol Cancer Ther. 2022 Feb;21(2):336-346. PMCID: PMC8828706

Keddy C, Neff T, Huan J, Nickerson JP, Beach CZ, Akkari Y, Ji J, Moore S, Nazemi KJ, Corless CL, Beadling C, Woltjer R, Cho YJ, Wood MD, Davare MA. Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion. Cold Spring Harb Mol Case Stud. 2021 Oct 19;7(5):a006109. PMCID: PMC8559620

Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021 Jan;18(1):35-55. PMCID: PMC8830365